Oblong Bolsters Decentralized AI Strategy with Bittensor ($TAO) Purchase and Staking
The $TAO investment underscores Oblong's focus on Bittensor's decentralized AI protocol, which fosters global collaboration in machine learning. By staking all 5,025 tokens in the Bittensor network, the Company is actively supporting the ecosystem while enhancing its treasury's performance. 'Oblong's initial $TAO purchase fulfills its commitment to a forward-thinking reserve while exploring Bittensor ecosystem partnerships, as $TAO's innovative AI approach offers compelling exposure to a rapidly growing sector,' said Peter Holst, CEO of Oblong.
This is the first of several planned investments in the Bittensor ecosystem, with Oblong evaluating additional $TAO purchases on a weekly basis. The Company is also exploring partnerships within the Bittensor ecosystem to potentially develop technology offerings, further aligning its operational and treasury strategies. Transparent updates on treasury performance, including staking yields and token holdings, will be provided in Oblong's Q2 2025 earnings results and at upcoming investor conferences.
About Oblong, Inc.
Oblong (Nasdaq: OBLG) is building a robust cryptocurrency treasury focused on decentralized artificial intelligence (AI) and the acquisition of $TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI. The Company also provides innovative video collaboration and network solutions, centered around our patented Mezzanine™ product line and managed services.
Forward-looking and cautionary statements
This press release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, that address activities that Oblong assumes, plans, expects, believes, intends, projects, estimates, or anticipates (and other similar expressions) will, should, or may occur in the future are forward-looking statements and include, but are not limited to, the intended use of proceeds from the Company's recent financing, and statements regarding market opportunity and the Company's new Bittensor-centric AI and digital asset strategy. Oblong's actual results may differ materially from its expectations, estimates, and projections, and consequently, you should not rely on these forward-looking statements as predictions of future events. Without limiting the generality of the foregoing, forward-looking statements contained in this press release include statements relating to the Company's plans to explore partnerships within the Bittensor ecosystem to potentially develop technology offerings. The forward-looking statements are based on management's current belief, based on currently available information, as to the outcome and timing of future events and involve factors, risks, and uncertainties, including market and other conditions and the volatility of market price for our securities, that may cause actual results in future periods to differ materially from such statements. A list and description of these and other risk factors can be found in the Company's Annual Report on Form 10-K for the year ending December 31, 2024, the Company's Form 8-K filed on June 6, 2025 and in other filings made by the Company with the SEC from time to time. Any of these factors could cause Oblong's actual results and plans to differ materially from those in the forward-looking statements. Therefore, the Company cannot give any assurance that its future results will be as estimated. The Company does not intend to, and disclaims any obligation to, correct, update, or revise any information contained herein.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Barclays bullish on Kimco, Federal Realty as it launches coverage of retail REITs
-- Barclays starts coverage of retail REITs, rating Kimco Realty (NYSE:KIM) and Federal Realty Investment Trust (NYSE:FRT) Overweight while it was Equal weight on Regency Centers (NASDAQ:REG), Phillips Edison, Simon Property Group (NYSE:SPG) and Tanger. The brokerage said investors appear to be overpaying for the perceived defensiveness of certain grocery‑anchored portfolios, yet Kimco itself offers a cheaper way to own that theme. Barclays said New York‑based landlord is a large cap, high‑quality, diversified 'proxy' for grocery‑anchored shopping centers, trading at a modest discount to peers and set for about 5% funds‑from‑operations (FFO) growth next year. Federal Realty, whose high‑end shopping districts span U.S. coastal markets, has lagged rivals since the pandemic but is shifting capital toward lower‑risk acquisitions and more modest redevelopments, the note said. While Regency, Phillips Edison, Simon and Tanger all look fairly valued, the broker wrote. Regency carries a three‑turn premium to the sector on forward FFO, Phillips Edison still trades above peers despite shrinking returns on recent acquisitions, and both Simon and Tanger face apparel‑heavy tenant rosters that could be squeezed further if tariffs rise. Barclays' sector outlook favours companies with strong balance sheets and improving free‑cash‑flow profiles, and is wary of REITs chasing FFO growth through acquisitions after a sharp compression in shopping‑center cap rates. While consumer spending and tariff risks loom, Kimco and Federal Realty still screen as the best risk‑reward ideas in a retail landscape adjusting to slower economic growth. Investors, the bank cautioned, should remember that 'investors may be overpaying for the perceived defensiveness of certain grocery‑anchored portfolios.' Related articles Barclays bullish on Kimco, Federal Realty as it launches coverage of retail REITs Roblox: What's behind the meteoric rise of 'Grow a Garden' Quantum Computing started at Neutral on steep valuation, slow commercialization Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Good news for investors: You don't have to start out with tons of cash to grow wealth. Biotech stocks offer you a great opportunity to get in on innovators that may produce major growth down the road. 10 stocks we like better than Viking Therapeutics › Some potential investors hesitate to get started on building an investment portfolio because they think they need thousands of dollars to grow wealth. But I've got good news for them and for you: You don't have to start out with a huge pile of cash to invest in stocks that may significantly add value to your portfolio over time. In fact, with just $200, you can get in on players that could help you along the path to wealth. The industry of biotech is a great place to look for such stocks since so many of these companies are developing cutting-edge technologies that may lead to high-growth products, and revenue, down the road. Let's consider two that you might buy today -- a few shares of each for a total of $200 -- and hold forever to benefit from lasting growth stories. Viking Therapeutics (NASDAQ: VKTX) aims to make its mark in one of today's (and tomorrow's) biggest healthcare growth areas: weight loss drugs. The biotech company is developing a dual GIP/GLP-1 receptor agonist, known as VK2735, and has progressed into late-stage clinical trials. The candidate, in injectable form, just launched its phase 3 program and aims to enroll more than 4,000 participants with obesity and more than 1,000 volunteers with obesity and type 2 diabetes. VK2735 works by interacting with hormonal pathways involved in the control of appetite and blood sugar levels, much like the already commercialized Mounjaro and Zepbound, sold by Eli Lilly, and Ozempic and Wegovy, sold by Novo Nordisk. But the fact that similar drugs have reached the market first doesn't mean Viking can't succeed here. Demand for these sorts of products has been so high that it exceeded supply, until Lilly and Novo Nordisk increased manufacturing capacity. So there's plenty of room for a young company like Viking to succeed here too if all continues to go well in clinical trials. Viking also is testing VK2735 in oral form in a phase 2 trial, an important point since oral formulation could make these drugs easier to take, and it involves faster and cheaper manufacturing processes for the company. Data from that trial is expected later this year. Viking stock is known to soar on positive results. It surged more than 120% last year in just one trading session after reporting positive phase 2 data for VK2735. It's since given up the gains, offering investors a solid entry point, but any good news and a possible regulatory nod could prompt the stock to skyrocket. Moderna (NASDAQ: MRNA) used to be a favorite of investors during the early days of the coronavirus pandemic -- but since, it's had trouble bringing investors back into its potential growth story. The stock has lost more than 90% since its peak back in 2021, and the company has reported decreasing sales because of the drop in demand for its coronavirus vaccine and lower-than-expected sales of its more recently launched respiratory syncytial virus (RSV) vaccine. After Moderna's billions of dollars in revenue and profit just a couple of years ago and recent earnings declines, investors may find it difficult to get excited about Moderna again. But it's important to remember two things: First, it's unfair to compare revenue potential during ordinary times to revenue linked to a pandemic-related product. Those were exceptional times that don't occur often. Second, the approval of Moderna's coronavirus and RSV vaccines show that its technology -- the technology driving the rest of its pipeline -- works. The company now has many late-stage products in the works and aims to launch as many as 10 over the next few years. If Moderna even makes it partially to that goal, its revenue picture a few years from now may look very different from the picture today -- and set the company up for long-term growth. It's too early to predict when the market will recognize this and flock to Moderna shares. But at today's level, the stock offers investors a buying opportunity, making it a great place to park part of your $200 and hold on for the long-term as this growth story develops. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna, Novo Nordisk, and Viking Therapeutics. The Motley Fool has a disclosure policy. Got $200? 2 Biotech Stocks to Buy and Hold Forever was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
IBN Coverage: D-Wave Quantum (NYSE: QBTS) Raises $400 Million Through Equity Offering
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - July 2, 2025 (NEWMEDIAWIRE) - D-Wave Quantum (NYSE: QBTS) ("D-Wave"), a leader in quantum computing systems, software, and services and the world's first commercial supplier of quantum computers, has completed sales of $400 million in gross proceeds of its common stock under its previously disclosed "at-the-market" ("ATM") equity offering program. The program, which ran from June 11 to June 27, closed at an average share price of $15.18. This represents a 149% premium over the $6.10 average share price for the sales under the company's prior $150 million ATM program completed in January. The Company intends to use the proceeds from this financing primarily for strategic acquisitions and general corporate purposes including additional working capital and capital expenditures. "With what we believe to be the strongest balance sheet of any public, independent quantum computing company, we intend to invest in acquisitions and programs that will enable us to expand our already significant lead as the only commercial quantum computing company with applications in production," said Dr. Alan Baratz, CEO of D-Wave. To view the full press release, visit About D-Wave Quantum Inc. D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world's first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers, the world's largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we're shaping the quantum-driven industrial and societal advancements of tomorrow: Forward Looking Statements Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to QBTS are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBNLos Angeles, OfficeEditor@ View the original release on Sign in to access your portfolio
